Intercept Pharma (ICPT) Tops Q3 EPS by 98c

Intercept Pharma (NASDAQ: ICPT) reported Q3 EPS of ($0.11), $0.98 better than the analyst estimate of ($1.09). Revenue for the quarter came in at $92.8 million versus the consensus estimate of $83.02 million.

GUIDANCE:

Intercept Pharma sees FY2021 revenue of $355-370 million, versus the consensus of $339 million.

For earnings history and earnings-related data on Intercept Pharma (ICPT) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c